Don't Repeat Europe's Vaccine Catastrophe


By Joel White

For many Americans, the calamitously slow vaccine roll-out in countries like Germany, France, and Italy comes as a surprise. After all, in the early days of the pandemic, Europe's response to the crisis seemed highly competent, especially compared to the United States.

But the sluggish vaccination campaign in these nations is actually quite predictable. For years, European policymakers have imposed strict price controls on new pharmaceuticals -- and those price caps have delayed patients' access to cutting-edge medicines. The same story is now playing out with Covid-19 vaccines.

Amazingly, Congress is now seeking to emulate Europe's failed price control policies. Europe's botched vaccine rollout ought to make lawmakers reconsider.

Four months after the first Covid-19 vaccine earned authorization, large portions of Europe are still struggling to inoculate their populations. In Germany, Italy, and France, only about 25 percent of patients have received at least one vaccine dose.

Consider that the United States -- which is far more populated than any of those three nations -- has administered at least one dose of the vaccine to over half the adult population, and has fully vaccinated three in ten people.

How to explain Europe's sluggish vaccine roll-out? While there is no single cause, one major factor is the European Union's obsession with paying less for Covid-19 immunizations than many other countries. Whereas Israel -- by far the world leader in Covid-19 vaccinations -- agreed to pay $25 for each dose, and the United States paid $20, the EU held out for a discount, ultimately paying $15 to $19.

And while EU countries got a lower price, they paid more in other ways. A recent analysis found that the delayed rollout could cost the European economy close to $107 billion this year. That's more than four times what the EU paid for its vaccines.

Sadly, this isn't the first time Europe's price-obsessed bureaucracy has delayed access to lifesaving new medicines. It's routine for agencies like Germany's Federal Joint Committee and France's Economic Committee for Health Products to set prices for breakthrough drugs at below-market rates. And it's because of these tactics that new medicines generally take far longer to reach European patients.

There were 290 new active pharmaceutical substances released worldwide between 2011 and 2018. Of those, German patients had access to just under two thirds, and just under half were offered to French patients.

Meanwhile, in America -- where policymakers have so far eschewed European-style price-controls -- patients had access to nearly 90 percent of these new treatments.

Despite the damage wrought by Europe's drug price controls, many American lawmakers remain eager to copy these policies. House Democrats just revived H.R. 3, a bill that would tie prices for up to 250 common medicines covered by Medicare to the average price paid in other rich nations -- Germany and France among them.

Europe's catastrophic vaccine rollout has shown the high cost, in money and lives, of price controls. Importing those policies here would have disastrous consequences for American patients and end up costing us all more in the long run.

Joel White is president of the Council for Affordable Health Coverage, a coalition of organizations seeking to lower the cost of health care for all Americans. Previously, Joel spent 12 years on Capitol Hill as a House staffer, most recently as the Staff Director for the Ways and Means Health Subcommittee.

More Resources


06/01/2024
Biden Has Gotten His Wish--and It Won't Help
The truth is Donald Trump being a convicted felon won't change your opinion of him. In fact, now some Republicans are more likely to vote for him.

more info


06/01/2024
The Martyr of Mar-a-Lago
Trump can never be wrong; he can only be wronged.

more info


06/01/2024
Voters Increasingly Worried About the Rule of Law
I opposed the Republican attempt to use the personal life of Bill Clinton to impeach him, and this attempt to use the personal life of Donald Trump to jail him is no different.

more info


06/01/2024
The Big Biden Panic
President Joe Biden is trailing, but perhaps the guilty verdict against Trump will save him.

more info


06/01/2024
Thank God Case Was Brought in a State With No GOP Control
MSNBC host Joy Reid calls out Black Republican leaders decrying former President Donald Trump's guilty verdict.

more info


06/01/2024
Republicans Vow To Scorch the Earth After Trump Conviction
Spurred by the volcanic temper of their base, Republicans are now preparing to scorch the earth in the wake of former President Donald Trump's conviction, potentially setting off a chain reaction that could fundamentally alter the American political system entirely.

more info


06/01/2024
Democrat Lawyers Are Running Rings Around Republicans
Either you're willing to jail Democrats on the same terms they're using to jail Trump, or you're merely controlled opposition.

more info


06/01/2024
What the Biden Campaign Thinks the Verdict Means


more info


06/01/2024
This Was a Typical Communist Show Trial
In November, we have what may be our last chance to save this country-not just make our country great again, but to make it greater than it has ever been.

more info


06/01/2024
Kennedy Fights for Game-Changing Spot on Debate Stage


more info


06/01/2024
The Ghost of Covid Past Looms Over Gen Z Voters


more info


06/01/2024
In Major Escalation Biden Allows U.S. Arms To Strike in Russia


more info


06/01/2024
Triumvirate of Pols, Lobbyists, Pentagon Hurt U.S.


more info


06/01/2024
How To Help Affordable Housing Problem-Solvers


more info


06/01/2024
My Enemies
In conversation with Russ Roberts

more info



Custom Search

More Politics Articles:

Related Articles

Cancer Cures May Already Exist — But Won't Reach Patients if Pelosi's Drug Bill Passes


House Democrats recently unveiled H.R. 3, a proposal that would impose ill-considered price controls on prescription drugs.

Senate Drug Plan Brings Death and Taxes


The Prescription Drug Pricing Reduction Act would stall future drug development and deprive Americans of lifesaving cures -- all without reducing patients' out-of-pocket costs.

Is the Federal Reserve Apolitical?


President Donald Trump has had (what else?) a publicly tempestuous relationship with the Federal Reserve System.

The Bladensburg Cross: The Court Moves in the Right Direction


A large cross erected in 1925 by Gold Star mothers in honor of their 49 fallen sons who gave their lives in World War I will be allowed to stand. That is the U.S. Supreme Court's decision in American Legion v. American Humanist Association. The monument, located in Prince George's County, Maryland, has been maintained by a state agency—the Maryland National Capital Parks and Planning Commission—with government funds since 1961. Members of the American Humanist Association claimed they were offended when driving past this religious symbol maintained on public land at public expense, and that to continue this display was a violation of the Constitutional provision prohibiting a governmental "establishment of religion."

Impeachment of the President: Who Should We Consult? We Say the Founders


Impeachment was in the news recently after President Donald Trump's personal attorney, Michael Cohen, pleaded guilty to campaign finance violations. In his plea, Cohen implicated Trump, stating that he, as Trump's attorney, had made payments to women at the direction of a "candidate for federal office." Some journalists jumped with joy at the news, as captured by headlines like this in the New York Times: "Donald Trump's High Crimes and Misdemeanors: The Principled Case for Impeachment is Clear, What is Missing is the Courage."

Are Fossil Fuels an Ethical Investment?


Saudi oil giant Aramco -- the world's most profitable company -- issued its first public offering in December. The IPO has reenergized debate around whether it's ethical to invest in oil and natural gas companies.

Texas Firms Save Lives and Healthcare Dollars


Rising healthcare costs are taking their toll on American patients. Half of adults say they or a loved one skipped or delayed treatment in the past year due to cost concerns, according to the Kaiser Family Foundation. About a quarter say they or a family member has struggled to pay medical bills.

Bring IP Back Into US-Japan


If you blinked, you might have missed it. On January 1, a limited trade deal between the United States and Japan took effect. It doesn't go nearly far enough.

Curbing U.S. Population Growth Would Fight Climate Change


Millions of young Americans want to shrink their carbon footprints.

We Can Save the Planet Without Destroying the Economy


More than 250 environmental groups recently petitioned House Democratic leaders to embrace the Green New Deal. They claim banning fossil fuels is the key to ending climate change.

American Innovation Helps Patients Beat Coronavirus


American scientists are working furiously to develop treatments for the novel coronavirus, COVID-19.

When Protectionism Endangers Lives


Peter Navarro, one of President Trump's trade advisors, recently slammed pharmaceutical lobbyists for opposing his "Buy American" executive order.

Coronavirus Reveals the Recklessness of Drug Pricing Reform


A Seattle patient recently became the first American to receive a potential breakthrough vaccine for COVID-19. That vaccine -- developed by Moderna, a Massachusetts biotech start-up -- is one of several experimental coronavirus vaccines and treatments that pharmaceutical firms are developing around the country.

America's Unique Approach to Innovation Will Cure COVID-19


Scientists have responded to COVID-19 with unprecedented speed. Just months after the outbreak of the novel coronavirus, clinical trials are already underway for nearly 200 vaccines and therapies.

Trump Proves Black Workers Matter


President Trump recently suspended nearly all guest-worker programs for the rest of the year. This historic executive order will open up more than 500,000 jobs to Americans -- and it'll disproportionately help Black citizens.